IO Biotech 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   1 Trial   10 News 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IO102 / IO Biotech
KIEO, NCT05977907: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Recruiting
2
15
US
Pembrolizumab, Keytruda, IO102-103
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, IO Biotech, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
10/26
10/28
IO112 / IO Biotech
2019-001434-34: Dual Vaccine Trial in Myeloproliferative Neoplasms

Not yet recruiting
1/2
48
Europe
ARGLong2, PD-L1Long1, Concentrate and solvent for solution for injection
Department of haematology, Zealand university hospital, Novo nordisk, Kræftens bekæmpelse, IO biotech
Myeloproliferative Neoplasms, Myeloproliferative Neoplasms, a group of cancer diseases of the bonemarrow in which excess cells are produced., Diseases [C] - Cancer [C04]
 
 
Cylembio (imsapepimut and etimupepimut, adjuvanted) / IO Biotech
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
2020-000120-19: Activity and safety of a vaccine in head and neck cancer

Not yet recruiting
2
30
Europe
IO102 + Montanide ISA 51 VG Sterile, IO103 + Montanide ISA 51 VG Sterile, IO102-IO103 + Montanide ISA 51 VG Sterile, IO102, IO103, IO102-IO103, Emulsion for emulsion for injection, Emulsion for injection
Cliniques universitaires Saint-Luc, IoBiotech ApS
Head and neck cancer elective for surgery, Head and neck cancer elective for surgery, Diseases [C] - Cancer [C04]
 
 
2021-003026-69: A study investigating the use of IO102-IO103 in combination with pembrolizumab for patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or metastatic Urothelial Bladder Cancer (mUBC)

Not yet recruiting
2
90
Europe
IO102-IO103 + Montanide ISA 51 VG Sterile, Emulsion for injection
IO Biotech ApS, IO Biotech ApS
Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC) cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) metastásico, carcinoma urotelial de vejiga metastásico (CUVm), Lung Cancer, Head and Neck Cancer, Bladder Cancer Cáncer de pulmón, cáncer de cabeza y cuello, cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Active, not recruiting
2
63
Europe, US
IO102-IO103 in combination with pembrolizumab
IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
01/24
11/24
NCT04445064 / 2020-000120-19: Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

Recruiting
2
17
Europe
IO102, IO103
Cliniques universitaires Saint-Luc- Université Catholique de Louvain, IoBiotech ApS
Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
06/24
06/24
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting
2
60
Europe, US, RoW
IO102-IO103, Pembrolizumab KEYTRUDA®
IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC
Melanoma, Squamous Cell Carcinoma of Head and Neck
04/25
01/27
NCT05912244: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Recruiting
2
43
US
IO102/IO103, Nivolumab-Relatlimab
Memorial Sloan Kettering Cancer Center, IO Biotech
Melanoma
06/27
06/27
NCT03047928 / 2016-004527-23: Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Completed
1/2
48
Europe
Nivolumab, Opdivo, PD-L1/IDO peptide vaccine, IO102/IO103 peptide vaccine
Inge Marie Svane
Metastatic Melanoma
12/22
12/22
NCT05843448: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Recruiting
1
30
US
PD-L1/IDO Peptide Vaccine, IO102-IO103 Peptide Vaccine, IO103/IO102 Peptide Vaccine, PD-L1/IDO Peptide, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of California, Davis, IO Biotech, National Cancer Institute (NCI)
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
06/26
12/26
IO-160 / IO Biotech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IO102 / IO Biotech
KIEO, NCT05977907: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Recruiting
2
15
US
Pembrolizumab, Keytruda, IO102-103
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, IO Biotech, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
10/26
10/28
IO112 / IO Biotech
2019-001434-34: Dual Vaccine Trial in Myeloproliferative Neoplasms

Not yet recruiting
1/2
48
Europe
ARGLong2, PD-L1Long1, Concentrate and solvent for solution for injection
Department of haematology, Zealand university hospital, Novo nordisk, Kræftens bekæmpelse, IO biotech
Myeloproliferative Neoplasms, Myeloproliferative Neoplasms, a group of cancer diseases of the bonemarrow in which excess cells are produced., Diseases [C] - Cancer [C04]
 
 
Cylembio (imsapepimut and etimupepimut, adjuvanted) / IO Biotech
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
2020-000120-19: Activity and safety of a vaccine in head and neck cancer

Not yet recruiting
2
30
Europe
IO102 + Montanide ISA 51 VG Sterile, IO103 + Montanide ISA 51 VG Sterile, IO102-IO103 + Montanide ISA 51 VG Sterile, IO102, IO103, IO102-IO103, Emulsion for emulsion for injection, Emulsion for injection
Cliniques universitaires Saint-Luc, IoBiotech ApS
Head and neck cancer elective for surgery, Head and neck cancer elective for surgery, Diseases [C] - Cancer [C04]
 
 
2021-003026-69: A study investigating the use of IO102-IO103 in combination with pembrolizumab for patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or metastatic Urothelial Bladder Cancer (mUBC)

Not yet recruiting
2
90
Europe
IO102-IO103 + Montanide ISA 51 VG Sterile, Emulsion for injection
IO Biotech ApS, IO Biotech ApS
Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC) cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) metastásico, carcinoma urotelial de vejiga metastásico (CUVm), Lung Cancer, Head and Neck Cancer, Bladder Cancer Cáncer de pulmón, cáncer de cabeza y cuello, cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Active, not recruiting
2
63
Europe, US
IO102-IO103 in combination with pembrolizumab
IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
01/24
11/24
NCT04445064 / 2020-000120-19: Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

Recruiting
2
17
Europe
IO102, IO103
Cliniques universitaires Saint-Luc- Université Catholique de Louvain, IoBiotech ApS
Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
06/24
06/24
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting
2
60
Europe, US, RoW
IO102-IO103, Pembrolizumab KEYTRUDA®
IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC
Melanoma, Squamous Cell Carcinoma of Head and Neck
04/25
01/27
NCT05912244: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Recruiting
2
43
US
IO102/IO103, Nivolumab-Relatlimab
Memorial Sloan Kettering Cancer Center, IO Biotech
Melanoma
06/27
06/27
NCT03047928 / 2016-004527-23: Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Completed
1/2
48
Europe
Nivolumab, Opdivo, PD-L1/IDO peptide vaccine, IO102/IO103 peptide vaccine
Inge Marie Svane
Metastatic Melanoma
12/22
12/22
NCT05843448: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Recruiting
1
30
US
PD-L1/IDO Peptide Vaccine, IO102-IO103 Peptide Vaccine, IO103/IO102 Peptide Vaccine, PD-L1/IDO Peptide, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of California, Davis, IO Biotech, National Cancer Institute (NCI)
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
06/26
12/26
IO-160 / IO Biotech
No trials found

Download Options